APA

Gisslinger H., Klade C., Georgiev P., Krochmalczyk D., Gercheva-Kyuchukova L., Egyed M., Rossiev V., Dulicek P., Illes A., Pylypenko H., Sivcheva L., Mayer J., Yablokova V., Krejcy K., Grohmann-Izay B., Hasselbalch H. C., Kralovics R. & Kiladjian J. (20200311). Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. : The Lancet. Haematology.

Chicago

Gisslinger Heinz, Klade Christoph, Georgiev Pencho, Krochmalczyk Dorota, Gercheva-Kyuchukova Liana, Egyed Miklos, Rossiev Viktor, Dulicek Petr, Illes Arpad, Pylypenko Halyna, Sivcheva Lylia, Mayer Jiri, Yablokova Vera, Krejcy Kurt, Grohmann-Izay Barbara, Hasselbalch Hans C, Kralovics Robert and Kiladjian Jean-Jacques. 20200311. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. : The Lancet. Haematology.

Harvard

Gisslinger H., Klade C., Georgiev P., Krochmalczyk D., Gercheva-Kyuchukova L., Egyed M., Rossiev V., Dulicek P., Illes A., Pylypenko H., Sivcheva L., Mayer J., Yablokova V., Krejcy K., Grohmann-Izay B., Hasselbalch H. C., Kralovics R. and Kiladjian J. (20200311). Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. : The Lancet. Haematology.

MLA

Gisslinger Heinz, Klade Christoph, Georgiev Pencho, Krochmalczyk Dorota, Gercheva-Kyuchukova Liana, Egyed Miklos, Rossiev Viktor, Dulicek Petr, Illes Arpad, Pylypenko Halyna, Sivcheva Lylia, Mayer Jiri, Yablokova Vera, Krejcy Kurt, Grohmann-Izay Barbara, Hasselbalch Hans C, Kralovics Robert and Kiladjian Jean-Jacques. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. : The Lancet. Haematology. 20200311.